Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD79b CAR-T cells
- Development stage
- Phase 1
- Lead developer
- YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD79b CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Zhejiang University for the treatment of B-cell malignancies. The therapy consists of autologous T cells genetically modified to express a CAR targeting CD79b, a transmembrane protein that forms part of the B-cell receptor (BCR) complex and is highly expressed on the surface of mature B cells and most B-cell lymphomas and leukemias. By targeting CD79b, these engineered T cells are designed to recognize and eliminate malignant B cells. This specific murine-derived CAR-T construct is currently being evaluated in Phase 1 clinical trials to assess its safety and efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL).
- Other names
- Murine CD79b CAR-T Cellsanti-CD79b CAR-T cellsanti-CD-79b CAR-T cellsanti-CD 79b CAR-T cells
02
Targets
B-cell antigen receptor complex-associated protein beta chain
Beyond the preview
Go deeper on CD79b CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD79b CAR-T cells.